Valbenazine Reduces Tardive Dyskinesia, With Good TolerabilityValbenazine Reduces Tardive Dyskinesia, With Good Tolerability

In the phase 3 KINECT 3 trial, investigational drug valbenazine reduced tardive dyskinesia among psychiatric patients receiving antipsychotic medications, with a favorable safety profile. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news